Literature DB >> 18032768

Lenalidomide--the phoenix rises.

Alan F List.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18032768     DOI： 10.1056/NEJMe078203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

2.  Myeloma therapy-a new paradigm.

Authors:  Archie W Brown
Journal:  Ochsner J       Date:  2008

3.  Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Authors:  Jodi A Muscal; Yongkai Sun; Jed G Nuchtern; Robert C Dauser; Leticia H McGuffey; Brian W Gibson; Stacey L Berg
Journal:  Cancer Chemother Pharmacol       Date:  2011-11-23       Impact factor: 3.333

Review 4.  Protracted disseminated skeletal metastases from angiosarcoma of the spleen.

Authors:  B Jobke; M Werner; G Jundt; H Ostertag; J Freyschmidt
Journal:  Clin Exp Metastasis       Date:  2010-02-21       Impact factor: 5.150

5.  Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authors:  Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth Anderson
Journal:  Core Evid       Date:  2010-06-15

6.  Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

Authors:  Sharon L Sanborn; Joseph Gibbons; Smitha Krishnamurthi; Joanna M Brell; Afshin Dowlati; Joseph A Bokar; Charles Nock; Nancy Horvath; Jacob Bako; Scot C Remick; Matthew M Cooney
Journal:  Invest New Drugs       Date:  2008-11-15       Impact factor: 3.850

Review 7.  Can we change the disease biology of multiple myeloma?

Authors:  Ivan Borrello
Journal:  Leuk Res       Date:  2012-11       Impact factor: 3.156

8.  A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Authors:  Yiming Chen; Hagop Kantarjian; Zeev Estrov; Stefan Faderl; Farhad Ravandi; Kristy Rey; Jorge Cortes; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-10

9.  Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

Authors:  Ashley A Basiorka; Kathy L McGraw; Leentje De Ceuninck; Lori N Griner; Ling Zhang; Justine A Clark; Gisela Caceres; Lubomir Sokol; Rami S Komrokji; Gary W Reuther; Sheng Wei; Jan Tavernier; Alan F List
Journal:  Cancer Res       Date:  2016-04-06       Impact factor: 12.701

10.  Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.

Authors:  Ota Fuchs
Journal:  Leuk Res Treatment       Date:  2012-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.